Palatin Technologies Past Earnings Performance
Past criteria checks 0/6
Palatin Technologies's earnings have been declining at an average annual rate of -31.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 66.5% per year.
Key information
-31.4%
Earnings growth rate
-27.5%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -66.5% |
| Return on equity | n/a |
| Net Margin | -1,357.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Palatin Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -32 | 11 | 0 |
| 30 Jun 24 | 4 | -30 | 12 | 0 |
| 31 Mar 24 | 6 | -31 | 13 | 0 |
| 31 Dec 23 | 7 | -32 | 15 | 0 |
| 30 Sep 23 | 6 | -21 | 15 | 0 |
| 30 Jun 23 | 5 | -24 | 15 | 0 |
| 31 Mar 23 | 4 | -27 | 17 | 0 |
| 31 Dec 22 | 3 | -26 | 16 | 0 |
| 30 Sep 22 | 2 | -37 | 16 | 0 |
| 30 Jun 22 | 1 | -36 | 17 | 0 |
| 31 Mar 22 | 1 | -37 | 16 | 0 |
| 31 Dec 21 | 1 | -35 | 17 | 0 |
| 30 Sep 21 | 0 | -37 | 19 | 0 |
| 30 Jun 21 | 0 | -34 | 17 | 0 |
| 31 Mar 21 | 0 | -27 | 15 | 0 |
| 31 Dec 20 | 0 | -27 | 13 | 0 |
| 30 Sep 20 | 0 | -22 | 10 | 0 |
| 30 Jun 20 | 0 | -22 | 10 | 0 |
| 31 Mar 20 | 60 | 37 | 10 | 0 |
| 31 Dec 19 | 60 | 37 | 10 | 0 |
| 30 Sep 19 | 60 | 37 | 9 | 0 |
| 30 Jun 19 | 60 | 36 | 10 | 0 |
| 31 Mar 19 | 21 | -5 | 9 | 0 |
| 31 Dec 18 | 30 | 0 | 10 | 0 |
| 30 Sep 18 | 40 | 8 | 9 | 0 |
| 30 Jun 18 | 67 | 25 | 9 | 0 |
| 31 Mar 18 | 80 | 26 | 8 | 0 |
| 31 Dec 17 | 82 | 23 | 10 | 0 |
| 30 Sep 17 | 72 | 10 | 10 | 0 |
| 30 Jun 17 | 45 | -13 | 10 | 0 |
| 31 Mar 17 | 11 | -40 | 10 | 0 |
| 31 Dec 16 | 0 | -49 | 6 | 0 |
| 30 Sep 16 | 0 | -52 | 6 | 0 |
| 30 Jun 16 | 0 | -52 | 6 | 0 |
| 31 Mar 16 | 0 | -50 | 6 | 0 |
| 31 Dec 15 | 0 | -47 | 6 | 0 |
| 30 Sep 15 | 8 | -31 | 6 | 0 |
| 30 Jun 15 | 13 | -18 | 6 | 0 |
| 31 Mar 15 | 13 | -10 | 5 | 0 |
| 31 Dec 14 | 13 | -2 | 5 | 0 |
| 30 Sep 14 | 5 | -9 | 5 | 0 |
| 30 Jun 14 | 0 | -14 | 5 | 0 |
| 31 Mar 14 | 0 | -14 | 5 | 11 |
Quality Earnings: 0KF3 is currently unprofitable.
Growing Profit Margin: 0KF3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0KF3 is unprofitable, and losses have increased over the past 5 years at a rate of 31.4% per year.
Accelerating Growth: Unable to compare 0KF3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0KF3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 0KF3's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.